Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Status:
Terminated
Trial end date:
2018-12-24
Target enrollment:
Participant gender:
Summary
The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and
the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH) The Foundation for Barnes-Jewish Hospital